Latest news with #NetraAI
Toronto Star
28-07-2025
- Business
- Toronto Star
NetraMark Signs Contract with AlgoTx to Enhance Clinical Trial Design for ATX01
TORONTO, July 28, 2025 (GLOBE NEWSWIRE) — NetraMark Holdings Inc. (the 'Company' or 'NetraMark') (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and AlgoTherapeutix SAS ('AlgoTx'), a clinical-stage biotechnology company developing first-in-class therapies for chemotherapy-induced peripheral neuropathy (CIPN) today announced they have entered into an agreement. Under this agreement, NetraMark will deploy its NetraAI platform to analyze patient-level data from AlgoTx's ATX01 program. NetraAI's unique technology will enable deep exploration of drug and placebo response variables, identification of responder personas, and delivery of enrichment strategies to inform the design of future ATX01 trials.
Hamilton Spectator
28-07-2025
- Business
- Hamilton Spectator
NetraMark Signs Contract with AlgoTx to Enhance Clinical Trial Design for ATX01
TORONTO, July 28, 2025 (GLOBE NEWSWIRE) — NetraMark Holdings Inc. (the 'Company' or 'NetraMark') (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and AlgoTherapeutix SAS ('AlgoTx'), a clinical-stage biotechnology company developing first-in-class therapies for chemotherapy-induced peripheral neuropathy (CIPN) today announced they have entered into an agreement. Under this agreement, NetraMark will deploy its NetraAI platform to analyze patient-level data from AlgoTx's ATX01 program. NetraAI's unique technology will enable deep exploration of drug and placebo response variables, identification of responder personas, and delivery of enrichment strategies to inform the design of future ATX01 trials. AlgoTx has established itself as a forward-thinking innovator committed to improving the lives of patients suffering from CIPN, with non opioid solutions. The company's decision to partner with NetraMark underscores its dedication to leveraging cutting-edge technologies to optimize trial design, with the goal of accelerating development timelines. NetraAI's unique methodology goes beyond traditional AI and machine learning tools by identifying and characterizing highly specific patient personas, enabling sponsors like AlgoTx to reduce placebo response, improve signal detection, and enrich trial populations with the most responsive patients—all critical factors in driving trial success. 'AlgoTx is a leader in bringing innovation to Complex Pain treatments,' said Josh Spiegel, President of NetraMark. 'Their decision to partner with us reflects the growing recognition that explainable, precision AI can unlock value from clinical datasets that conventional approaches overlook. We look forward to supporting their team in seeking to enhance trial design and accelerate progress for patients in need.' 'At AlgoTx, we are committed to integrating innovation at every stage of development to unlock new therapeutic possibilities for patients living with CIPN,' said Stephane Thiroloix, Founder and Chairman of the Board of Directors. 'This agreement reflects our commitment to applying best-in-class innovation at every stage of our pipeline to ensure we bring transformative therapies to patients as efficiently as possible.' NetraMark's work will include the development of customized AI models and interactive tools that allow the AlgoTx team to test hypotheses, vary clinical significance thresholds, and precisely characterize patient subpopulations. The collaboration will focus on generating validated, explainable, and regulator-ready insights to optimize future studies. About NetraMark NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. For further details on the Company please see the Company's publicly available documents filed on the System for Electronic Document Analysis and Retrieval+ (SEDAR+). For more NetraMark information, see the company's website and follow NetraMark on LinkedIn . About AlgoTherapeutix (AlgoTx) AlgoTherapeutix (AlgoTx) is a clinical stage biotechnology company developing a targeted, first in class therapeutic for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline for use in chemotherapy-induced peripheral neuropathy (CIPN), an area of high unmet need associated with unbearable pain in patients' extremities and for which there is currently no viable treatment options. ATX01 targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. Its topical administration has been designed to provide targeted relief from the excruciating pain in patients' extremities from CIPN, which is caused by nerve degeneration and is a common side effect of cancer treatment, occurring in 68% of patients. ATX01 was granted FDA fast track development status in CIPN. The company has completed recruitment and supporting analysis of data of its international Phase 2 clinical trial of 276 patients with CIPN (the 'ACT' study). The company has seasoned leadership, with experience of bringing global products successfully to market, and is backed by an international board. AlgoTx raised a Series B round of EUR 20 million in 2023 and has raised EUR 35 million to date. AlgoTx has a consortium of investors including Relyens Innovation Santé / Turenne Capital, who led the Series B fund raise, along with UI Investissement, and angel investors. Historical investors include Bpifrance through its Innobio 2 fund and Omnes Capital. For more information, see the company's website and follow AlgoTx on LinkedIn . Forward-Looking Statements This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation including statements regarding the potential capabilities of the NetraAI platform to explore drug and placebo response variables, identify responder personas, reduce placebo response, improve signal detection, more precisely characterize patient subpopulations, deliver strategies to inform and improve trial design, accelerate development timelines and generate validated, explainable and regulator-ready insights to optimize future studies which are based upon NetraMark's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as 'expect', 'likely', 'may', 'will', 'should', 'intend', 'anticipate', 'potential', 'proposed', 'estimate' and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions 'may', 'would' or 'will' happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at including our Management's Discussion and Analysis for the year ended September 30, 2024. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information. The CSE does not accept responsibility for the adequacy or accuracy of this release. Contact Information: Swapan Kakumanu - CFO | swapan@ | 403-681-2549
Business Upturn
12-06-2025
- Business
- Business Upturn
NetraMark Founder Coauthors New Publication on AI/ML Use in Clinical Trials, Alongside Authors From Leading Global Regulatory Organizations
TORONTO, June 12, 2025 (GLOBE NEWSWIRE) — NetraMark Holdings Inc. (the 'Company' or 'NetraMark') (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence (AI) solutions company transforming clinical trial design in the pharmaceutical industry through streamlined access to actionable analytics uncovered by AI, today announced that NetraMark founder Dr. Joseph Geraci was the lead author on a new publication that outlines the market opportunity for AI/ML to improve data quality and patient outcomes in clinical development. This manuscript, now available in the Journal of the Society for Clinical Data Management (JSCDM), is titled 'Current Opportunities for the Integration and Use of AI/ML in Clinical Trials: Good Clinical Practice Perspectives .' It identifies the ideal conditions and prerequisites for the use of emerging AI applications in clinical trials and the importance of aligning these technologies with Good Clinical Practice (GCP). Dr. Joseph Geraci, Founder, CSO, and CTO of NetraMark, contributed to this collaborative effort alongside individuals affiliated with organizations such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Danish Medicines Agency (DKMA), Pfizer, Sanofi, Neurocrine Biosciences, Saama Technologies, Relation Therapeutics, Cognizant Technology Solutions, and Wega Informatik AG. These contributions represent the personal views of the authors and not the official positions of their respective organizations. Drawing on the collective insights of regulators, sponsors, and technology developers, this publication explores the multifaceted landscape of AI/ML applications, where AI can deliver measurable benefits while ensuring compliance, transparency, patient safety, efficiency, accuracy, and overall effectiveness of clinical trials, specifically through seven real-world use cases: Smart Data Query Data Attributability Challenges in Wearable Device Data Enhancing Protocol Deviation Trending External Control Arms Streamlining Complaint Handling Patient Stratification in Diagnosis Patient Enrichment for Placebo/Drug Response Additionally, the manuscript highlights several challenges and ethical considerations facing AI/ML adoption in clinical trial, including: Challenges Generalizability – how well AI models can perform beyond their original training, testing, and validation data Provenance – the decisions, implicit or hidden, that were made in the creation of a model Effective clinical trialist-AI/ML interaction Ethical Considerations Robust, multi-layered privacy controls Trustworthy AI that is lawful, ethical, and technically and socially robust Built for Compliance, Designed for Impact: How NetraAI's Capabilities Align with Industry Needs Built from the ground up to advance the impact that AI can have on clinical trial enrichment, NetraAI goes beyond traditional AI assessments to provide a specialized solution for small or sparse dataset modeling, addressing the key conclusions of the JSCDM manuscript: Explainability and Auditability Data Quality Monitoring and Anomaly Detection Patient Stratification and Enrichment Mitigation of Placebo Response Multi-modal Data Integration Explainability and Auditability Ethical and Regulatory Alignment 'It was an honor to contribute to this significant review alongside respected voices from across the global regulatory and pharmaceutical landscape,' said Dr. Joseph Geraci, Founder, CSO, and CTO of NetraMark. 'NetraMark is committed to working with sponsors to realize the benefits of AI/ML adoption in traditional clinical trial processes. Our collective work underscores the opportunities for NetraAI to help set the standards in the pharmaceutical industry and establish the best use of AI/ML and ethical compliance for clinical trial evolution.' This review is available to the public at . About NetraMark NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. Forward-Looking Statements This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation including statements regarding the potential use of NetraMark's AI solutions to drive intelligent, patient-centric clinical trial optimization, the optimization of clinical trials by uncovering hidden patient subpopulations, how NetraAI may address the key conclusions of the JSCDM manuscript, the integration of NetraMark's AI as a dedicated solution to advance clinical trial success, NetraMark's commitment to working with sponsors to realize the benefits of AI/ML adoption in traditional clinical trial processes, opportunities for NetraAI to help set standards in the pharmaceutical industry, the establishment of best practices for AI/ML use and ethical compliance, and the advancement of technological capabilities of clinical trial enrichment, which are based upon NetraMark's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as 'expect', 'likely', 'may', 'will', 'should', 'intend', 'anticipate', 'potential', 'proposed', 'estimate' and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions 'may', 'would' or 'will' happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at including our Management's Discussion and Analysis for the year ended September 30, 2024. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information. The CSE does not accept responsibility for the adequacy or accuracy of this release. Contact Information: Swapan Kakumanu – CFO | [email protected] | 403-681-2549 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
